IPOs are expected to price this week
), which is developing a combination therapy in Phase 3 trial for
metastatic colorectal cancer, plans to raise $49 million by
offering 3.3 million shares at a price range of $14.00 to $16.00.
At the midpoint of the proposed range, Audeo Oncology would
command a market value of $163 million. Audeo Oncology, which was
founded in 2006, booked $0 million in sales over the last 12
months. The San Francisco, CA-based company plans to list on the
NASDAQ under the symbol AURX. Leerink Swann and Oppenheimer &
Co. are the joint bookrunners on the deal.
Renaissance Capital will have
available on each of these upcoming IPOs prior to its pricing.
Last week, there were 3
. SolarCity (
), which leases and installs solar energy systems for homes and
businesses, was the week's winner, ending up 47% from its IPO